株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

リキッドバイオプシーおよびその他非侵襲癌診断市場 (第3版):2019年~2030年

Liquid Biopsy and Other Non-Invasive Cancer Diagnostics Market (3rd Edition), 2019-2030: Focus on Circulating Tumor Markers such as CTCs, ctDNA, cfDNA, Exosomes and Other Biomarkers

発行 ROOTS ANALYSIS 商品コード 344666
出版日 ページ情報 英文 375 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=109.11円で換算しております。
リキッドバイオプシーおよびその他非侵襲癌診断市場 (第3版):2019年~2030年 Liquid Biopsy and Other Non-Invasive Cancer Diagnostics Market (3rd Edition), 2019-2030: Focus on Circulating Tumor Markers such as CTCs, ctDNA, cfDNA, Exosomes and Other Biomarkers
出版日: 2019年10月31日 ページ情報: 英文 375 Pages
概要

癌は、世界における主要な死因のひとつです。2019年には、米国だけで約60万人が癌が原因で死亡したと推定されています。さらに、世界保健機関は、今後20年間で新たな癌の症例数が70%増加すると推測しています。癌の死亡率が高い主な理由のひとつは、診断の遅れだと考えられています。その結果として、治療が遅れ、生存の可能性が大きく低下します。長年にわたり、組織生検は癌診断のゴールドスタンダードと考えられてきましたが、この検査手法は侵襲的であるため、検査を頻繁に繰り返して疾患の進行を評価/測定したり、治療結果をモニタリングしたりすることはできません。また、患部よっては、そのような侵襲的処置を受けることができないため、生検を実施することはできません。これにより、正確な検査結果を提供できる、より安全でより患者に優しい癌診断手法に対するアンメットニーズが生まれています。

当レポートは、世界の非侵襲癌診断市場について取り上げ、各種の癌診断に用いられる上市・開発中のリキッドバイオプシーキット/アッセイ、およびその他の新しい・有望な非侵襲診断に関する調査を提供しており、市場の概要、市場規模と予測、および主要企業のプロファイルなどをまとめ、お届け致します。

第1章 序論

第2章 エグゼクティブサマリー

第3章 イントロダクション

  • 本章の概要
  • 癌統計・疾病負担
  • 癌における早期発見の重要性
  • 癌の検診と診断
  • 従来の侵襲性癌診断検査
    • 生検
    • 内視鏡
  • 非侵襲アプローチの必要性
  • リキッドバイオプシー:血中バイオマーカーの診断
    • 血中循環腫瘍細胞
    • 血中循環腫瘍DNA
    • エキソソーム
  • 非侵襲検査関連のコスト・メリット
  • 非侵襲性癌診断に関連する知的財産の新たな動向
  • 非侵襲性癌診断に関連する課題
  • 将来展望

第4章 非侵襲癌スクリーニング・診断

  • 本章の概要
  • 診断画像
  • スクリーニングアッセイ
  • 先進非侵襲アプローチ

第5章 市場情勢

  • 本章の概要
  • リキッドバイオプシー製品:ディベロッパーの一覧
  • リキッドバイオプシー製品:現在利用可能な製品と開発中の製品の一覧
  • リキッドバイオプシー製品:その他の製品・キット・消耗品の一覧
  • リキッドバイオプシー製品:受託サービスプロバイダーの一覧

第6章 企業プロファイル

  • 本章の概要
  • Amoy Diagnostics
  • DiaCarta
  • HaploX
  • NeoGenomics
  • QIAGEN
  • Swift Biosciences
  • Sysmex Inostics
  • Thermo Fisher Scientific

第7章 提携・協業状況

  • 本章の概要
  • 提携モデル
  • 提携・協業一覧

第8章 資金調達・投資分析

  • 本章の概要
  • 資金調達の種類
  • 資金調達・投資一覧
  • 備考

第9章 リキッドバイオプシー:大手製薬企業のイニシアチブ

  • 本章の概要
  • 主要製薬企業

第10章 主な買収標的

  • 本章の概要
  • 調査範囲
  • スコアリングの基準と主要な前提条件
  • 北米の潜在的な戦略的買収標的
  • 欧州のの潜在的な戦略的買収標的
  • アジア太平洋地域/その他の地域の潜在的買収標的
  • 備考

第11章 その他の非侵襲癌診断

  • 本章の概要
  • 非血液ベースのバイオマーカー検出検査
  • 便潜血反応検査 (FOBT) ・免疫便潜血検査 (FIT)
  • 色素性病変アッセイ
  • 便DNA (sDNA) 検査
  • 揮発性有機化合物 (VOC) 検出検査
  • その他の非侵襲癌診断:市場情勢

第12章 市場規模・機会分析

  • 本章の概要
  • 予測の前提条件・予測手法
  • 世界の非侵襲癌診断市場の予測

第13章 調査インサイト

  • 本章の概要
  • 回答者の企業詳細
  • 回答者の指定
  • 製品ポートフォリオのタイプ
  • 提供される製品/サービスの種類
  • 適用分野
  • 製品の開発状況
  • 市場規模

第14章 結論

第15章 エグゼクティブインサイト

第16章 付録1:表形式のデータ

第17章 付録2:企業と組織の一覧

図表

List of Figures

  • Figure 3.1 Worldwide Incidence of Cancer: Distribution by Indication
  • Figure 3.2 Lung Cancer: Estimated New Cases in 2018 (in Thousands)
  • Figure 3.3 Breast Cancer: Estimated New Cases in 2018 (in Thousands)
  • Figure 3.4 Colorectal Cancer: Estimated New Cases in 2018 (in Thousands)
  • Figure 3.5 Factors Determining Useful Cancer Screening
  • Figure 3.6 Conventional Cancer Diagnosis Methods
  • Figure 3.7 Disadvantages of Conventional Cancer Diagnosis Methods
  • Figure 3.8 Circulating Biomarkers for Cancer Detection
  • Figure 3.9 Traditional Biopsy: Process Flow
  • Figure 3.10 Non-Invasive Biopsy: Process Flow
  • Figure 3.11 Non-Invasive Cancer Diagnostics: Year-wise Distribution of Patents
  • Figure 4.1 Broad Categories of Non-Invasive Cancer Screening and Diagnostics
  • Figure 4.2 Types of Diagnostic Imaging
  • Figure 4.3 Types of Screening Assays
  • Figure 4.4 Types of Advanced Non-Invasive Approaches for Cancer Diagnosis
  • Figure 5.1 Liquid Biopsy Developers: Distribution by Year of Establishment
  • Figure 5.2 Liquid Biopsy Developers: Distribution by Company Size and Geographical Location
  • Figure 5.3 Liquid Biopsy Developers: Leading Players
  • Figure 5.4 Liquid Biopsy Developers: Distribution by Geographical Location of Developer
  • Figure 5.5 Liquid Biopsy Products: Distribution by Status of Development
  • Figure 5.6 Liquid Biopsy Products: Distribution by Type of Product
  • Figure 5.7 Liquid Biopsy Products: Distribution by Application Area
  • Figure 5.8 Venn Diagram Representation: Distribution by Application Area
  • Figure 5.9 Liquid Biopsy Products: Distribution by Target Cancer Indication
  • Figure 5.10 Liquid Biopsy Products: Distribution by Type of Tumor Marker
  • Figure 5.11 Liquid Biopsy Products: Distribution by Type of Tumor Marker and Application Area
  • Figure 5.12 Liquid Biopsy Products: Distribution by End User
  • Figure 5.13 Liquid Biopsy Products: Distribution by Turnaround Time
  • Figure 6.1 Amoy Diagnostics: Annual Revenues, FY2016 - FY2018 (CNY Million)
  • Figure 6.2 NeoGenomics: Annual Revenues, FY2014 - FY2018 (USD Million)
  • Figure 6.3 QIAGEN: Annual Revenues, FY2014 - FY2018 (USD Billion)
  • Figure 6.4 Thermo Fisher Scientific: Annual Revenues, FY2014 - FY2018 (USD Billion)
  • Figure 7.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2016-2019
  • Figure 7.2 Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 7.3 Partnerships and Collaborations: Year-wise Trend by Type of Partnership (2016-2019)
  • Figure 7.4 Partnerships and Collaborations: Distribution by Type of Tumor Marker
  • Figure 7.5 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Tumor Marker
  • Figure 7.6 Partnerships and Collaborations: Distribution by Target Cancer Indication
  • Figure 7.7 Partnerships and Collaborations: Distribution by Type of Partnership and Target Cancer Indication
  • Figure 7.8 Partnerships and Collaborations: Distribution by Year and Type of Partners
  • Figure 7.9 Partnerships and Collaborations: Most Active Players
  • Figure 7.10 Partnerships and Collaborations: Regional Distribution
  • Figure 7.11 Partnerships and Collaborations: Intercontinental and Intracontinental Partnerships
  • Figure 8.1 Funding and Investment Analysis: Distribution by Type of Funding and Year of Establishment of Receiving Companies, 2015-2019
  • Figure 8.2 Funding and Investment Analysis: Cumulative Year-wise Trend, 2015-2019
  • Figure 8.3 Funding and Investment Analysis: Cumulative Amount Invested, 2015-2019 (USD Million)
  • Figure 8.4 Funding and Investment Analysis: Distribution of Instances by Type of Funding, 2015-2019
  • Figure 8.5 Funding and Investment Analysis: Distribution of the Total Amount Invested by Type of Funding, 2015-2019 (USD Million)
  • Figure 8.6 Funding and Investment Analysis: Summary of Investments, 2015-2019 (USD Million)
  • Figure 8.7 Funding and Investment Analysis: Distribution by Instances Across Different Types of Indications
  • Figure 8.8 Funding and Investment Analysis: Distribution by Number of Instances and Amount Invested Across Different Types of Tumor Marker
  • Figure 8.9 Funding and Investment Analysis: Most Active Players, 2015 - 2019 (USD Million)
  • Figure 8.10 Funding and Investment Analysis: Most Active Investors
  • Figure 8.11 Funding and Investment Analysis: Distribution by Geography
  • Figure 8.12 Funding and Investment Analysis: Regional Distribution of Funding Instances
  • Figure 8.13 Funding and Investment Summary, 2015-2019 (USD Million)
  • Figure 9.1 Big Pharma Players: Heat Map Analysis of Top Pharmaceutical Companies
  • Figure 9.2 Big Pharma Players: Analysis by Status of Development
  • Figure 9.3 Big Pharma Players: Analysis by Type of Tumor Marker
  • Figure 9.4 Big Pharma Players: Analysis by Type of Application Area
  • Figure 9.5 Big Pharma Players: Analysis by Target Cancer Indication
  • Figure 10.1 Likely Acquisition Targets: Geographical Distribution
  • Figure 12.1 Global Non-Invasive Cancer Diagnostics Market, 2019-2030 (USD Million)
  • Figure 12.2 Global Liquid Biopsy Market, 2019-2030 (USD Million)
  • Figure 12.3 Global Liquid Biopsy Market: Distribution by Application Area, 2019, 2030
  • Figure 12.4 Global Liquid Biopsy Market for Early Diagnosis, 2019-2030 (USD Million)
  • Figure 12.5 Global Liquid Biopsy Market for Patient Monitoring, 2019-2030 (USD Million)
  • Figure 12.6 Global Liquid Biopsy Market for Recurrence Monitoring, 2019-2030 (USD Million)
  • Figure 12.7 Global Liquid Biopsy Market: Distribution by Target Cancer Indication, 2019, 2030
  • Figure 12.8 Global Liquid Biopsy Market for Breast Cancer, 2019-2030 (USD Million)
  • Figure 12.9 Global Liquid Biopsy Market for Lung Cancer, 2019-2030 (USD Million)
  • Figure 12.10 Global Liquid Biopsy Market for Colorectal Cancer, 2019-2030 (USD Million)
  • Figure 12.11 Global Liquid Biopsy Market for Prostate Cancer, 2019-2030 (USD Million)
  • Figure 12.12 Global Liquid Biopsy Market for Bladder Cancer, 2019-2030 (USD Million)
  • Figure 12.12 Global Liquid Biopsy Market for Melanoma, 2019-2030 (USD Million)
  • Figure 12.14 Global Liquid Biopsy Market for Gastric Cancer, 2019-2030 (USD Million)
  • Figure 12.15 Global Liquid Biopsy Market for Pancreatic Cancer, 2019-2030 (USD Million)
  • Figure 12.16 Global Liquid Biopsy Market for Ovarian Cancer, 2019-2030 (USD Million)
  • Figure 12.17 Global Liquid Biopsy Market: Distribution by Type of Tumor Marker, 2019, 2030
  • Figure 12.18 Global Liquid Biopsy Market for ctDNA, 2019-2030 (USD Million)
  • Figure 12.19 Global Liquid Biopsy Market for cfDNA, 2019-2030 (USD Million)
  • Figure 12.20 Global Liquid Biopsy Market for CTCs, 2019-2030 (USD Million)
  • Figure 12.21 Global Liquid Biopsy Market for Exosomes, 2019-2030 (USD Million)
  • Figure 12.22 Global Liquid Biopsy Market for Other Tumor Markers, 2019-2030 (USD Million)
  • Figure 12.23 Global Liquid Biopsy Market: Distribution by Type of Analyte, 2019, 2030
  • Figure 12.24 Global Liquid Biopsy Market for Blood, 2019-2030 (USD Million)
  • Figure 12.25 Global Liquid Biopsy Market for Other Body Fluids, 2019-2030 (USD Million)
  • Figure 12.26 Global Liquid Biopsy Market: Distribution by End User, 2019, 2030
  • Figure 12.27 Global Liquid Biopsy Market for Hospitals, 2019-2030 (USD Million)
  • Figure 12.28 Global Liquid Biopsy Market for Research Institutes, 2019-2030 (USD Million)
  • Figure 12.29 Global Liquid Biopsy Market for Other End Users, 2019-2030 (USD Million)
  • Figure 12.30 Global Liquid Biopsy Market: Distribution by Geography, 2019, 2030
  • Figure 12.31 Liquid Biopsy Market in the US, 2019-2030, By Value (USD Million)
  • Figure 12.32 Liquid Biopsy Market in the US, By Volume, 2019-2030 (Million Units)
  • Figure 12.33 Liquid Biopsy Market in the UK, By Value, 2019-2030 (USD Million)
  • Figure 12.34 Liquid Biopsy Market in the UK, By Volume, 2019-2030 (Million Units)
  • Figure 12.35 Liquid Biopsy Market in Germany, By Value, 2019-2030 (USD Million)
  • Figure 12.36 Liquid Biopsy Market in Germany, By Volume, 2019-2030 (Million Units)
  • Figure 12.37 Liquid Biopsy Market in France, By Value, 2019-2030 (USD Million)
  • Figure 12.38 Liquid Biopsy Market in France, By Volume, 2019-2030 (Million Units)
  • Figure 12.39 Liquid Biopsy Market in Italy, By Value, 2019-2030 (USD Million)
  • Figure 12.40 Liquid Biopsy Market in Italy, By Volume, 2019-2030 (Million Units)
  • Figure 12.41 Liquid Biopsy Market in Spain, By Value, 2019-2030 (USD Million)
  • Figure 12.42 Liquid Biopsy Market in Spain, By Volume, 2019-2030 (Million Units)
  • Figure 12.43 Liquid Biopsy Market in Japan, By Value, 2019-2030 (USD Million)
  • Figure 12.44 Liquid Biopsy Market in Japan, By Volume, 2019-2030 (Million Units)
  • Figure 12.45 Liquid Biopsy Market in China, By Value, 2019-2030 (USD Million)
  • Figure 12.46 Liquid Biopsy Market in China, By Volume, 2019-2030 (Million Units)
  • Figure 12.47 Liquid Biopsy Market in India, By Value, 2019-2030 (USD Million)
  • Figure 12.48 Liquid Biopsy Market in India, By Volume, 2019-2030 (Million Units)
  • Figure 12.49 Liquid Biopsy Market in Australia, By Value, 2019-2030 (USD Million)
  • Figure 12.50 Liquid Biopsy Market in Australia, By Volume, 2019-2030 (Million Units)
  • Figure 12.51 Other Non-Invasive Cancer Diagnostics Market: 2019-2030 (USD Million)
  • Figure 13.1 Survey Insights: Distribution of Respondents by Year of Establishment of Company
  • Figure 13.2 Survey Insights: Distribution of Respondents by Company Size
  • Figure 13.3 Survey Insights: Distribution of Respondents by Location of Company Headquarters (Country-wise)
  • Figure 13.4 Survey Insights: Distribution by Designation and Seniority Level
  • Figure 13.5 Survey Insights: Distribution by Type of Product Portfolio
  • Figure 13.6 Survey Insights: Distribution by Type of Products / Services Offered
  • Figure 13.7 Survey Insights: Distribution by Application Area
  • Figure 13.8 Survey Insights: Distribution by Status of Development of the Products
  • Figure 13.9 Survey Insights: Likely Liquid Biopsy Market Size (2030)
  • Figure 13.10 Survey Insights: Likely Other Non-Invasive Cancer Diagnostics Market Size (2030)
  • Figure 14.1 Non-Invasive Cancer Diagnostics Market (USD Million), 2019, 2025 and 2030

List of Tables

  • Table 3.1 Survival on Early Diagnosis of Cancer
  • Table 3.2 Cost of Biopsy for Different Cancer Indications (in USD)
  • Table 3.3 Common Endoscopic Procedures
  • Table 4.1 Examples of Tumor Markers
  • Table 5.1 Liquid Biopsy Products: Developer Overview
  • Table 5.2 Liquid Biopsy Products: List of Available / Under Development Products
  • Table 5.3 Liquid Biopsy Products: List of Additional Products
  • Table 5.4 Liquid Biopsy Products: List of Other Kits and Consumables
  • Table 5.5 Liquid Biopsy Products: List of Contract Service Providers
  • Table 6.1 Non-Invasive Cancer Diagnostics: List of Profiled Companies
  • Table 6.2 Amoy Diagnostics: Company Snapshot
  • Table 6.3 Amoy Diagnostics: Product Portfolio
  • Table 6.4 Amoy Diagnostics: Recent Developments and Future Outlook
  • Table 6.5 DiaCarta: Company Snapshot
  • Table 6.6 DiaCarta: Product Portfolio
  • Table 6.7 DiaCarta: Recent Developments and Future Outlook
  • Table 6.8 HaploX: Company Snapshot
  • Table 6.9 HaploX: Product Portfolio
  • Table 6.10 HaploX: Recent Developments and Future Outlook
  • Table 6.11 NeoGenomics: Company Snapshot
  • Table 6.12 NeoGenomics: Product Portfolio
  • Table 6.13 NeoGenomics: Recent Developments and Future Outlook
  • Table 6.14 QIAGEN: Company Snapshot
  • Table 6.15 QIAGEN: Product Portfolio
  • Table 6.16 QIAGEN: Recent Developments and Future Outlook
  • Table 6.17 Swift Biosciences: Company Snapshot
  • Table 6.18 Swift Biosciences: Product Portfolio
  • Table 6.19 Swift Biosciences: Recent Developments and Future Outlook
  • Table 6.20 Sysmex Inostics: Company Snapshot
  • Table 6.21 Sysmex Inostics: Product Portfolio
  • Table 6.22 Sysmex Inostics: Recent Developments and Future Outlook
  • Table 6.23 Thermo Fisher Scientific: Company Snapshot
  • Table 6.24 Thermo Fisher Scientific: Product Portfolio
  • Table 6.25 Thermo Fisher Scientific: Recent Developments and Future Outlook
  • Table 7.1 Non-Invasive Cancer Diagnostics: Partnerships and Collaborations, 2016-2019
  • Table 8.1 Non-Invasive Cancer Diagnostics Market: Funding and Investments, 2015-2019
  • Table 8.2 Funding and Investment Analysis: Summary of Investments
  • Table 10.1 North America: Most Likely Partners for Acquisition
  • Table 10.2 Europe: Most Likely Partners for Acquisition
  • Table 10.3 Asia-Pacific / Rest of the World: Most Likely Partners for Acquisition
  • Table 11.1 Other Non-Invasive Cancer Diagnostics: Market Landscape
  • Table 13.1 Survey Insights: Overview of Respondents
  • Table 13.2 Survey Insights: Designation and Seniority Levels
  • Table 13.3 Survey Insights: Type of Product Portfolio
  • Table 13.4 Survey Insights: Type of Products / Services Offered
  • Table 13.5 Survey Insights: Application Area
  • Table 13.6 Survey Insights: Status of Development of the Products
  • Table 13.7 Survey Insights: Likely Liquid Biopsy Market Size (2030)
  • Table 13.8 Survey Insights: Likely Other Non-Invasive Cancer Diagnostics Market Size
  • Table 16.1 Liquid Biopsy Developers: Distribution by Year of Establishment
  • Table 16.2 Liquid Biopsy Developers: Distribution by Company Size and Geographical Location
  • Table 16.3 Liquid Biopsy Developers: Leading Players
  • Table 16.4 Liquid Biopsy Products: Distribution by Status of Development
  • Table 16.5 Liquid Biopsy Products: Distribution by Type of Product
  • Table 16.6 Liquid Biopsy Products: Distribution by Application Area
  • Table 16.7 Liquid Biopsy Products: Distribution by Target Cancer Indication
  • Table 16.8 Liquid Biopsy Products: Distribution by Type of Tumor Marker
  • Table 16.9 Liquid Biopsy Products: Distribution by End User
  • Table 16.10 Liquid Biopsy Products: Distribution by Turnaround Time
  • Table 16.11 Amoy Diagnostics: Annual Revenues, FY2016-FY2018 (CNY Million)
  • Table 16.12 NeoGenomics: Annual Revenues, FY2014 - FY2018 (EUR Million)
  • Table 16.13 QIAGEN: Annual Revenues, FY2014 - FY2018 (EUR Billion)
  • Table 16.14 Thermo Fisher Scientific: Annual Revenues, FY2014 - FY2018 (EUR Billion)
  • Table 16.15 Partnerships and Collaborations: Cumulative Year-wise Trend, 2016-2019
  • Table 16.16 Partnerships and Collaborations: Distribution by Type of Partnership
  • Table 16.17 Partnerships and Collaborations: Year-wise Trend by Type of Partnership, 2016-2019
  • Table 16.18 Partnerships and Collaborations: Distribution by Type of Tumor Marker
  • Table 16.19 Partnerships and Collaborations: Distribution by Target Cancer Indication
  • Table 16.20 Partnerships and Collaborations: Distribution by Year and Type of Partners
  • Table 16.21 Partnerships and Collaborations: Most Active Players
  • Table 16.22 Partnerships and Collaborations: Regional Distribution
  • Table 16.23 Funding and Investment Analysis: Cumulative Number of Instances by Year, 2015-2019
  • Table 16.24 Funding and Investment Analysis: Cumulative Amount Invested, 2015-2019 (USD Million)
  • Table 16.25 Funding and Investment Analysis: Distribution of Instances by Type of Funding, 2015-2019
  • Table 16.26 Funding and Investment Analysis: Distribution of the Total Amount Invested by Type of Funding, 2015-2019 (USD Million)
  • Table 16.27 Funding and Investments: Distribution by Number of Instances and Amount Invested Across Different Types of Tumor Marker
  • Table 16.28 Funding and Investment Analysis: Most Active Players, 2015-2019 (USD Million)
  • Table 16.29 Funding and Investment Analysis: Most Active Investors
  • Table 16.30 Funding and Investment Analysis: Regional Distribution of Funding Instances
  • Table 16.31 Global Non-Invasive Cancer Diagnostics Market, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
  • Table 16.32 Global Liquid Biopsy Market, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
  • Table 16.33 Global Liquid Biopsy Market: Distribution by Application Area, 2019, 2030
  • Table 16.34 Global Liquid Biopsy Market for Early Diagnosis, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
  • Table 16.35 Global Liquid Biopsy Market for Patient Monitoring, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
  • Table 16.36 Global Liquid Biopsy Market for Recurrence Monitoring, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
  • Table 16.37 Global Liquid Biopsy Market: Distribution by Target Cancer Indication, 2019, 2030
  • Table 16.38 Global Liquid Biopsy Market for Breast Cancer, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
  • Table 16.39 Global Liquid Biopsy Market for Lung Cancer, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
  • Table 16.40 Global Liquid Biopsy Market for Colorectal Cancer, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
  • Table 16.41 Global Liquid Biopsy Market for Prostate Cancer, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
  • Table 16.42 Global Liquid Biopsy Market for Bladder Cancer, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
  • Table 16.43 Global Liquid Biopsy Market for Melanoma, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
  • Table 16.44 Global Liquid Biopsy Market for Gastric Cancer, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
  • Table 16.45 Global Liquid Biopsy Market for Pancreatic Cancer, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
  • Table 16.46 Global Liquid Biopsy Market for Ovarian Cancer, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
  • Table 16.47 Global Liquid Biopsy Market: Distribution by Type of Tumor Marker, 2019, 2030
  • Table 16.48 Global Liquid Biopsy Market for ctDNA, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
  • Table 16.49 Global Liquid Biopsy Market for cfDNA, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
  • Table 16.50 Global Liquid Biopsy Market for CTCs, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
  • Table 16.51 Global Liquid Biopsy Market for Exosomes, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
  • Table 16.52 Global Liquid Biopsy Market for Other Tumor Markers, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
  • Table 16.53 Global Liquid Biopsy Market: Distribution by Type of Analyte, 2019, 2030
  • Table 16.54 Global Liquid Biopsy Market for Blood, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
  • Table 16.55 Global Liquid Biopsy Market for Other Body Fluids, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
  • Table 16.56 Global Liquid Biopsy Market: Distribution by End User, 2019, 2030
  • Table 16.57 Global Liquid Biopsy Market for Hospitals, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
  • Table 16.58 Global Liquid Biopsy Market for Research Institutes, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
  • Table 16.59 Global Liquid Biopsy Market for Other End Users, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
  • Table 16.60 Global Liquid Biopsy Market: Distribution by Geography, 2019, 2030
  • Table 16.61 Liquid Biopsy Market in the US, By Value, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
  • Table 16.62 Liquid Biopsy Market in the US, By Volume, Conservative, Base, and Optimistic Scenario, 2019-2030 (Million Units)
  • Table 16.63 Liquid Biopsy Market in the UK, By Value, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
  • Table 16.64 Liquid Biopsy Market in the UK, By Volume, Conservative, Base, and Optimistic Scenario, 2019-2030 (Million Units)
  • Table 16.65 Liquid Biopsy Market in Germany, By Value, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
  • Table 16.66 Liquid Biopsy Market in Germany, By Volume, Conservative, Base, and Optimistic Scenario, 2019-2030 (Million Units)
  • Table 16.67 Liquid Biopsy Market in France, By Value, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
  • Table 16.68 Liquid Biopsy Market in France, By Volume, Conservative, Base, and Optimistic Scenario, 2019-2030 (Million Units)
  • Table 16.69 Liquid Biopsy Market in Italy, By Value, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
  • Table 16.70 Liquid Biopsy Market in Italy, By Volume, Conservative, Base, and Optimistic Scenario, 2019-2030 (Million Units)
  • Table 16.71 Liquid Biopsy Market in Spain, By Value, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
  • Table 16.72 Liquid Biopsy Market in Spain, By Volume, Conservative, Base, and Optimistic Scenario, 2019-2030 (Million Units)
  • Table 16.73 Liquid Biopsy Market in Japan, By Value, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
  • Table 16.74 Liquid Biopsy Market in Japan, By Volume, Conservative, Base, and Optimistic Scenario, 2019-2030 (Million Units)
  • Table 16.75 Liquid Biopsy Market in China, By Value, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
  • Table 16.76 Liquid Biopsy Market in China, By Volume, Conservative, Base, and Optimistic Scenario, 2019-2030 (Million Units)
  • Table 16.77 Liquid Biopsy Market in India, By Value, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
  • Table 16.78 Liquid Biopsy Market in India, By Volume, Conservative, Base, and Optimistic Scenario, 2019-2030 (Million Units)
  • Table 16.79 Liquid Biopsy Market in Australia, By Value, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
  • Table 16.80 Liquid Biopsy Market in Australia, By Volume, Conservative, Base, and Optimistic Scenario, 2019-2030 (Million Units)
  • Table 16.81 Other Non-Invasive Cancer Diagnostics Market, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
  • Table 16.82 Survey Insights: Distribution of Respondents by Year of Establishment of Company
  • Table 16.83 Survey Insights: Distribution of Respondents by Company Size
  • Table 16.84 Survey Insights: Distribution of Respondents by Location of Company Headquarters (Country-wise)
  • Table 16.85 Survey Insights: Distribution by Designation and Seniority Level
  • Table 16.86 Survey Insights: Distribution by Type of Product Portfolio
  • Table 16.87 Survey Insights: Distribution by Type of Products / Services Offered
  • Table 16.88 Survey Insights: Distribution by Application Area
  • Table 16.89 Survey Insights: Distribution by Status of Development of the Products
  • Table 16.90 Survey Insights: Likely Liquid Biopsy Market Size (2030)
  • Table 16.91 Survey Insights: Likely Other Non-Invasive Cancer Diagnostics Market Size (2030)
  • Table 16.92 Non-Invasive Cancer Diagnostics Market (USD Million), 2019, 2025 and 2030

List of Companies

  • 1. 360 Capital Partners
  • 2. 4D Lifetec
  • 3. 50K Ventures
  • 4. 5AM Ventures
  • 5. 6 Dimensions Capital
  • 6. A&G Pharmaceutical
  • 7. Abbott
  • 8. Abcodia
  • 9. Accu Reference Medical Lab
  • 10. AccuraGen
  • 11. Ackermans & van Haaren
  • 12. Acobiom
  • 13. Acousys Biodevices
  • 14. Active Motif
  • 15. Acuamark Diagnostics
  • 16. ADC Therapeutics
  • 17. Addario Lung Cancer Medical Institute
  • 18. Admera Health
  • 19. Advanced Wave Sensors
  • 20. Affymetrix
  • 21. AGCT
  • 22. Agena Bioscience
  • 23. Agilent Technologies
  • 24. Agiomix
  • 25. Ahren Innovation Capital
  • 26. Alabama Capital Network
  • 27. Albert & Annas Minne Foundation
  • 28. Alentia Capital Alternativo
  • 29. Alexandria Venture Investments
  • 30. Alliance Global
  • 31. Ally Bridge Group
  • 32. Alychlo
  • 33. Amadix
  • 34. AMAL Therapeutics
  • 35. Amazon
  • 36. Amedes Group
  • 37. Amer International Group
  • 38. America's Choice Provider Network
  • 39. American Bio Services
  • 40. Amgen
  • 41. Amoy Diagnostics
  • 42. Anchor Molecular
  • 43. ANCON Medical
  • 44. Andreessen Horowitz
  • 45. ANGLE
  • 46. Anixa Biosciences
  • 47. Annoroad Gene Technology
  • 48. Anpac Bio
  • 49. Anthill Ventures
  • 50. Apostle
  • 51. Arboretum Ventures
  • 52. ARCH Venture Partners
  • 53. ArcherDX
  • 54. ARNA Genomics
  • 55. Arquer Diagnostics
  • 56. ArrayGenomics
  • 57. Arrow Diagnostics
  • 58. Artiman Ventures
  • 59. ARUP Laboratories
  • 60. ASB Ventures
  • 61. Asia Genomics
  • 62. ASPiRA LABS
  • 63. AstraZeneca
  • 64. Astrimmune
  • 65. Asuragen
  • 66. Aurum Ventures
  • 67. AVIVA Biosciences
  • 68. Balderton Capital
  • 69. Bangkok Molecular Genetics
  • 70. BARD1 Life Sciences
  • 71. BeAble Capital
  • 72. BeaconLBS
  • 73. Bellwether Bio
  • 74. Best Med Opinion
  • 75. Beth Israel Deaconess Medical Center
  • 76. Betta Pharmaceuticals
  • 77. Bezos Expeditions
  • 78. BGI Genomics
  • 79. Bill & Melinda Gates Foundation
  • 80. Biocartis
  • 81. Biocept
  • 82. BioChain
  • 83. Biodesix
  • 84. BioDiscovery
  • 85. Bioeconomy Capital
  • 86. BioFluidica
  • 87. BIOHAL
  • 88. BioHisto Maroc
  • 89. Biolidics
  • 90. Biological Dynamics
  • 91. BioMarCare Technologies
  • 92. BioMark Diagnostics
  • 93. BiomaRx
  • 94. BIOPROGNOS
  • 95. Bio-Rad Laboratories
  • 96. Biosearch Technologies
  • 97. BioSequence
  • 98. BioVeda China Fund (BVCF)
  • 99. BioVendor
  • 100. BioView
  • 101. Bioyong Technology
  • 102. BloodPAC
  • 103. Blue Pool Capital
  • 104. Bluestar Genomics
  • 105. BNO BIO
  • 106. Boehringer Ingelheim
  • 107. Boreal Genomics
  • 108. Boston Children's Hospital
  • 109. Breath Diagnostics
  • 110. BrightEdge Ventures
  • 111. Bristol-Myers Squibb
  • 112. BSN
  • 113. Burning Rock Biotech
  • 114. Cambridge Epigenetix
  • 115. Cambridge Innovation Capital
  • 116. Cambridge University
  • 117. CANCER-ID
  • 118. Canostix
  • 119. Capio Biosciences
  • 120. Capital Research and Management
  • 121. CareFirst BlueCross BlueShield
  • 122. Caris Life Sciences
  • 123. Cathay Fortune International
  • 124. CDBI Partners
  • 125. Celgene
  • 126. CellMax Life
  • 127. Celsee
  • 128. Checkmate Pharmaceuticals
  • 129. China Biotech Services
  • 130. China Merchants Securities International
  • 131. Chronix Biomedical
  • 132. CIRCULOGENE
  • 133. Cirina
  • 134. Cleveland Diagnostics
  • 135. Clinical Genomics
  • 136. Clinomics
  • 137. CloudHealth Genomics
  • 138. Cloudstone Venture Fund
  • 139. Co-Diagnostics
  • 140. Colorectal Cancer Alliance
  • 141. ConquerX
  • 142. CORE Diagnostics
  • 143. Cornerstone Total Return Fund
  • 144. Cowin Venture Capital
  • 145. CPH Capital
  • 146. CryoGene
  • 147. Cyclomics
  • 148. Cynvenio-Livzon Diagnostics
  • 149. Cytofind Diagnostics
  • 150. Cytosystems
  • 151. Data Collective
  • 152. Datar Cancer Genetics
  • 153. Decheng Capital
  • 154. Delee
  • 155. Denlux Capital
  • 156. DermTech
  • 157. DiaCarta
  • 158. DiaDx
  • 159. Diagnolita
  • 160. Diagnostics Development Hub
  • 161. DIAN Diagnostics
  • 162. Diatech Pharmacogenetics
  • 163. DiuVita Diagnostics
  • 164. DNA Labs India
  • 165. Dow Biomedica
  • 166. DT Capital
  • 167. Durviz
  • 168. EarlyDx
  • 169. EDP Biotech
  • 170. EKF Diagnostics
  • 171. Elypta
  • 172. EONE Diagnomics Genome Center
  • 173. Epic Sciences
  • 174. Epigenomics
  • 175. Eurobio Scientific
  • 176. Eurofins Biomnis
  • 177. European Association for Predictive, Preventive & Personalised Medicine
  • 178. European Commission
  • 179. European Organisation for Research and Treatment of Cancer
  • 180. Exact Sciences
  • 181. Exalt Diagnostics
  • 182. ExBiome
  • 183. Exosome Diagnostics
  • 184. Exosomics
  • 185. Expedeon
  • 186. Farö Capital
  • 187. Flagship Biosciences
  • 188. Fluxion Biosciences
  • 189. Fortune Fountain Capital
  • 190. Fosun Pharmaceutical
  • 191. Foundation Medicine
  • 192. Fountain Medical Development
  • 193. Fox Chase Cancer Center
  • 194. Franklin Templeton Investments
  • 195. Frederick National Laboratory for Cancer Research
  • 196. Freenome
  • 197. Fudan-Taizhou Institute of Health Sciences
  • 198. GEM Global Yield Fund
  • 199. GeneCast Biotechnology
  • 200. Generation Investment Management
  • 201. Geneseq Biosciences
  • 202. Genetics Research
  • 203. Genetracer Biotech
  • 204. GENEWIZ
  • 205. GENEXT
  • 206. Genomenon
  • 207. Genomic Health
  • 208. Genomics England
  • 209. Genomictree
  • 210. Genoptix
  • 211. Genostics
  • 212. GILUPI
  • 213. Glycanostics
  • 214. Good Health Capital
  • 215. GRAIL
  • 216. Great Lakes New England Clinical Validation Center
  • 217. Green Pine Capital Partners
  • 218. Guangzhou Wondfo Biotech
  • 219. Guardant Health
  • 220. Gunnar Nilsson Cancer Foundation
  • 221. GV
  • 222. Hadean Ventures
  • 223. HaploX
  • 224. HarlePhil Ventures
  • 225. HDFC
  • 226. HealthCor Partners Management
  • 227. HEDA Ventures
  • 228. Helice Genomic Sciences
  • 229. Helsinn Investment Fund
  • 230. Highlight Capital
  • 231. Hillhouse Capital Group
  • 232. hrmed.tech
  • 233. HuangPu River Capital (HPR)
  • 234. Hummingbird Diagnostics
  • 235. Hvidovre Hospital
  • 236. Hyderabad Angels
  • 237. ICBC International
  • 238. iCellate Medical
  • 239. Idinvest Partners
  • 240. iGenetic Diagnostics
  • 241. Ikonisys
  • 242. Illumina
  • 243. Immodulon Therapeutics
  • 244. Impact Lab
  • 245. Imperial Innovations
  • 246. IncellDx
  • 247. Indian Angel Network
  • 248. Inivata
  • 249. Innovative Diagnostic Laboratory
  • 250. Innovatus Capital Partners
  • 251. Inova Strategic Investments
  • 252. Inovio Pharmaceuticals
  • 253. Institut Jules Bordet
  • 254. Integrated Diagnostics Holdings
  • 255. International Medical Center
  • 256. Interpace Diagnostics
  • 257. Intezyne
  • 258. Inventures
  • 259. Invitek Molecular
  • 260. Invoke Capital
  • 261. IP Group
  • 262. BIO.be
  • 263. IPS Genomix
  • 264. IV Diagnostics
  • 265. Janssen Diagnostics
  • 266. Jennison Associates
  • 267. Johnson & Johnson Innovation
  • 268. Jointown Pharmaceutical Group
  • 269. JTS Health Partners
  • 270. Junson Capital
  • 271. Kaiser Permanente Ventures
  • 272. KEODES
  • 273. Kexin Capital
  • 274. LABLAB
  • 275. Laboratory for Advanced Medicine
  • 276. Lariat Biosciences
  • 277. Levine Cancer Institute
  • 278. Lexent Bio
  • 279. LifeArc
  • 280. LifeX
  • 281. Lilly Asia Ventures
  • 282. Limitless Earth
  • 283. Liquid Biotech
  • 284. Lonza
  • 285. Loyal Valley Capital
  • 286. LU Holding
  • 287. Lucence Diagnostics
  • 288. LungLife AI
  • 289. MagBio Genomics
  • 290. Martell Biosystems
  • 291. Maryland Venture Fund
  • 292. Mascots Medical and Laboratory Center
  • 293. Massive Genomics
  • 294. Matrix Partners China
  • 295. Mayo Clinic
  • 296. McKesson Ventures
  • 297. MDNA Life Sciences
  • 298. MDxHealth
  • 299. MedCDx
  • 300. MedGenome
  • 301. Medigen Biotechnology
  • 302. MediNcrease Health Plans
  • 303. MedStar Health
  • 304. Menarini Silicon Biosystems
  • 305. Merck
  • 306. Mercy BioAnalytics
  • 307. Metabolomic Technologies
  • 308. Metamark
  • 309. MGI Tech
  • 310. MiCareo
  • 311. Microgenomics
  • 312. Micromedic Technologies
  • 313. Milost Global
  • 314. Miltenyi Biotec
  • 315. Mindera
  • 316. Ministry of Health Singapore
  • 317. Minomic International
  • 318. MIODx
  • 319. miR Scientific
  • 320. MiRXES
  • 321. MolecularMatch
  • 322. MolecularMD
  • 323. MRM Proteomics
  • 324. multimmune
  • 325. Mumbai Angels
  • 326. Mursla
  • 327. Myriad Genetics
  • 328. Nan Fung Group
  • 329. Nanjing Kaiyuan Growth Capital Investments
  • 330. Nanostics
  • 331. NantHealth
  • 332. Natera
  • 333. National Cancer Institute
  • 334. National Institutes of Health
  • 335. National Taiwan University
  • 336. Naveris
  • 337. NEO New Oncology
  • 338. NeoGeneStar
  • 339. NeoGenomics
  • 340. Neon Therapeutics
  • 341. Netherlands Organization for Scientific Research
  • 342. NeuMoDx
  • 343. New Enterprise Associates
  • 344. New Jersey Economic Development Authority
  • 345. New Science Ventures
  • 346. NIRAMAI Health Analytix
  • 347. NM Genomix
  • 348. Nodexus
  • 349. N-of-One
  • 350. Nonacus
  • 351. Norgen Biotek
  • 352. North Carolina Biotechnology Center
  • 353. Novartis
  • 354. Novigenix
  • 355. nRichDX
  • 356. Nucleix
  • 357. NueHealth
  • 358. NuGEN
  • 359. NuView Life Sciences
  • 360. NVIGEN
  • 361. OHSU Knight Cancer Institute
  • 362. oncgnostics
  • 363. Oncimmune
  • 364. OncoCyte
  • 365. Oncode Institute
  • 366. Oncode Scientific
  • 367. OncoDNA
  • 368. Oncolys BioPharma
  • 369. Oncore Pharma
  • 370. OncoSeek
  • 371. OPKO Health
  • 372. OrbiMed Advisors
  • 373. Örebro University Hospital
  • 374. ORI Healthcare Fund
  • 375. Owlstone Medical
  • 376. Oxford Gene Technology
  • 377. Pacific Edge
  • 378. PANAGENE
  • 379. Pangaea Oncology
  • 380. Pantai Premier Pathology
  • 381. Paragon Genomics
  • 382. Parampara Fund
  • 383. ParkwayHealth Laboratory
  • 384. PathGroup
  • 385. Perceptive Advisors
  • 386. PeriRx
  • 387. Personal Genome Diagnostics
  • 388. Pfizer
  • 389. Pillar Biosciences
  • 390. pluriSelect Life Science
  • 391. Polaris Partners
  • 392. Polymedco
  • 393. Polymer Char
  • 394. Positive Bioscience
  • 395. Precipio
  • 396. Precision for Medicine
  • 397. Predicine
  • 398. Prescient Metabiomics
  • 399. Prevail Partners
  • 400. Prime Value Capital Management
  • 401. Progenetics
  • 402. Prognos
  • 403. Prosperico Venture
  • 404. Protagen Diagnostics
  • 405. PROVIDENS
  • 406. Provista Diagnostics
  • 407. QIAGEN
  • 408. Qianjiang Capital
  • 409. Quantitative Cancer Diagnostix (QCDx)
  • 410. Quest Diagnostics
  • 411. Quidel
  • 412. RA Capital Management
  • 413. RainDance Technologies
  • 414. Rarecells Diagnostics
  • 415. RareCyte
  • 416. Regionalt Cancercentrum
  • 417. Reig Jofre Future Health
  • 418. Resolution Bioscience
  • 419. ResourcePath
  • 420. RGCC Group
  • 421. Roche
  • 422. Rongsheng Investment
  • 423. R-Pharm
  • 424. RT Ventures
  • 425. Sabartech
  • 426. SAGA Diagnostics
  • 427. Saha Fund
  • 428. Sambrinvest
  • 429. Sangel Capital
  • 430. SanoLiBio
  • 431. Sarah Cannon Research Institute
  • 432. Savicell Diagnostics
  • 433. Savran Technologies
  • 434. SB China Venture Capital
  • 435. ScreenCell
  • 436. Seer
  • 437. Sequoia Capital
  • 438. SeraCare Life Sciences
  • 439. Sevident
  • 440. Shanghai Fosun Long March Medical Science
  • 441. Shenzhen Innovation Investment Group
  • 442. Sienna Cancer Diagnostics
  • 443. Simfo
  • 444. Singapore Diagnostics
  • 445. Singlera Genomics
  • 446. Skane University Hospital
  • 447. Société Régionale d'Investissement de Wallonie (SRIW)
  • 448. Sofina
  • 449. Sofinim
  • 450. Sofinnova Ventures
  • 451. SOPHiA GENETICS
  • 452. Speclipse
  • 453. StageZero Life Sciences
  • 454. STEMCELL Technologies
  • 455. Strand Life Sciences
  • 456. StrandSmart
  • 457. Streck
  • 458. Stroke Detection Plus
  • 459. Sungent BioVenture
  • 460. Sutter Hill Ventures
  • 461. Suzhou Kintor Pharmaceuticals
  • 462. Swift Biosciences
  • 463. Syncona Partners
  • 464. Sysmex Inostics
  • 465. T Rowe Price Associates
  • 466. Taiwan Government Industrial Development Bureau, Ministry of Economic
  • 467. Takara Bio
  • 468. TAKE2
  • 469. Takeda
  • 470. Tarvand Sina Tajhiz
  • 471. TATAA Biocenter
  • 472. Tech Transfer UPV
  • 473. Telegraph Hill Partners
  • 474. Temasek
  • 475. Tempus
  • 476. Tencent
  • 477. The Heritage Group
  • 478. The University of Texas MD Anderson Cancer Center
  • 479. The W Fund
  • 480. Theranosis Life Sciences
  • 481. Thermo Fisher Scientific
  • 482. THG Ventures
  • 483. Thrive Earlier Detection
  • 484. Todos Medical
  • 485. Torna Kapital
  • 486. Torpedo Diagnostics
  • 487. Tranzend
  • 488. TSH Biopharm
  • 489. Tymora Analytical Operations
  • 490. UCF Medical Investment
  • 491. United States Department of Veterans Affairs
  • 492. Unitus Ventures
  • 493. Universal Diagnostics
  • 494. University Campus Bio-Medico of Rome
  • 495. University of Alabama at Birmingham
  • 496. University of Minnesota
  • 497. University of Texas Health Science Center
  • 498. Varian Medical Systems
  • 499. Velox Biosystems
  • 500. Verily Life Sciences
  • 501. Viatar CTC Solutions
  • 502. Vienomics
  • 503. Vigilant Biosciences
  • 504. Vinsovier
  • 505. VisionGate
  • 506. VolitionRx
  • 507. Vortex Biosciences
  • 508. West Cancer Center
  • 509. Windham Venture Partners
  • 510. Wisemont Capital
  • 511. WntResearch
  • 512. Woodford Patient Capital Trust
  • 513. WRF Capital
  • 514. WS Investment
  • 515. WuXi NextCODE
  • 516. XboXLab
  • 517. X-ZELL
  • 518. Yahui Precision Medical Fund
  • 519. Yale School of Medicine
  • 520. Yi Fang Group
  • 521. Zehou Capital
  • 522. Zinexts Life Science
  • 523. Zodius
  • 524. Zogen Genética Molecular
目次

Overview:

Cancer is known to be one of the leading causes of death worldwide. In 2019, 0.6 million deaths due to cancer are estimated in the US alone. Moreover, the World Health Organization has estimated the number of new cancer cases to rise by 70% over the next 20 years. One of the primary reasons for the high mortality associated with this condition is believed to be late diagnosis. This results in delayed treatment, which severely compromises chances of survival. For many years, tissue biopsy has been considered the gold standard for cancer diagnosis. However, owing to the invasive nature of the test, biopsies cannot be repeated frequently to assess / measure disease progression or monitor therapeutic outcome. In fact, in some cases, it is not possible to carry out a biopsy because the affected tissue / organ is not amenable to undergo such a painful and traumatic procedure. This has resulted in a significant unmet need for safer and more patient friendly cancer diagnostics that are capable of offering accurate test results.

Advances in the field of biotechnology have enabled the establishment of several minimally invasive / non-invasive approaches for disease diagnosis. Amongst other promising diagnostic tools, liquid biopsy has emerged as a versatile and promising non-invasive cancer diagnostic tool. This procedure is based on the analysis of biofluids (such as blood, urine and / or plasma) in order to detect rare forms of biomarkers / tumor markers, such as circulating tumor cells (CTCs), circulating tumor DNA / RNA (ctNAs), circulating free DNA (cfDNA) and exosomes. Moreover, liquid biopsies have been demonstrated to be capable of assessing the stage of tumor at the time of sample extraction. Additionally, owing to the non-invasive nature of the test, it can be actively used to monitor / track changes in tumors, both before and during the course of treatment. Other than liquid biopsy, the cancer diagnostics market has witnessed the emergence of several other non-invasive diagnostic technologies, which are based on analytes that are either superficially located (such as skin lesions) and / or are expelled from the body (such as bronchial fluids and exhaled breath). Most of the non-invasive diagnostic techniques mentioned above are backed by clinical data, validating their relevance and applicability across several types of solid tumors (such as breast cancer, lung cancer, ovarian cancer and pancreatic cancer) and hematological malignancies (such as leukemia and lymphoma). In future, non-invasive cancer diagnosis methods, particularly liquid biopsies, are anticipated to replace the existing invasive diagnostic techniques.

Scope of the Report:

The 'Liquid Biopsy and Other Non-Invasive Cancer Diagnostics Market (3rd Edition), 2019-2030: Focus on Circulating Tumor Markers such as CTCs, ctDNA, cfDNA, Exosomes and Other Biomarkers' report provides an extensive study on liquid biopsy kits / assays that are either commercialized or are under development for diagnosis and / or monitoring of different types of cancer. In addition, it features an elaborate discussion on the likely future opportunity associated with such tests, over the next 10 years. Amongst other elements, the report includes:

  • A detailed review of the overall landscape of the non-invasive cancer diagnostics market, featuring information on the developers of such products and analyses based on a number of relevant parameters, such as year of establishment, company size, geographical location, current development status of proprietary liquid biopsy test (under development, research use only, and available), type of product (assay kit, software / algorithm and device), type of tumor marker analyzed (CTCs, ctDNA, cfDNA, exosomes, and others), key applications (early diagnosis, treatment selection, patient monitoring and recurrence monitoring), type of analyte used (blood, urine and others) and target cancer indications.
  • An analysis of the various partnerships pertaining to non-invasive cancer diagnostics, which have been established between 2016 and 2019, based on various parameters, such as type of partnership, year of partnership, type of tumor marker, target cancer indications and the most active players.
  • An analysis of the investments made in companies engaged in the development of non-invasive cancer diagnostics, including details of seed financing, venture capital financing, debt financing, grants, and capital raised via IPOs and subsequent public offerings.
  • An analysis of the initiatives of big pharma players , highlighting the key focus areas of such companies and analysis based on various relevant parameters, such as stage of development of their proprietary non-invasive cancer diagnostic test(s), key applications, type of tumor marker and target disease indications.
  • A detailed acquisition target analysis, taking into consideration the historical trend of the activity of the companies that have acquired other firms since 2016, and offering a means for other industry stakeholders to identify potential acquisition targets.
  • Elaborate profiles of the key players engaged in this domain, featuring a brief overview of the company, its financial information (if available), a detailed description of its product portfolio, recent developments and an informed future outlook.

One of the key objectives of the report was to estimate the existing market size and potential future growth opportunities for non-invasive cancer diagnostics. Based on various parameters, such as number of available / under development products and estimated annual adoption rates, we have provided an informed estimate on the likely evolution of the market over the period 2019-2030. The report also features the likely distribution of the current and forecasted opportunity across [A] type of tumor marker (ctDNA, cfDNA, CTCs, exosomes, and others), [B] key applications (early diagnosis, patient monitoring and recurrence monitoring), [C] target disease indications (breast cancer, lung cancer, colorectal cancer, prostate cancer, bladder cancer, melanoma, gastric cancer, pancreatic cancer, ovarian cancer, and others), [D] end users (hospitals, research institutes and others), and [E] key geographical regions (the US, the UK, Germany, Italy, Spain, France, Japan, Australia, China, India, and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.

The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders:

  • Shibichakravarthy Kannan, Founder and CEO, Theranosis Life Sciences
  • Abizar Lakdawalla, Founder, ProXeom
  • Philippe Nore, CEO and Co-founder, MiNDERA Corporation
  • Frank Szczepanski, President and CEO, IVDiagnostics
  • Mark Li, CEO, Resolution Bioscience
  • Brad Walsh, CEO, Minomic International
  • Joachim Fluhrer, Founder and Medical Director, Genostics
  • Anton Iliuk, President and Chief Technology Officer, Tymora Analytical Operations
  • Catalina Vasquez, Chief Operating Officer, Nanostics
  • Burkhard Jansen, Chief Medical Officer, DermTech
  • Christer Ericsson, Chief Scientific Officer, iCellate Medical
  • Jake Micallef, Chief Scientific Officer, VolitionRx
  • Nathalie Bernard, Marketing Director, OncoDNA
  • Riccardo Razzini, Sales and Marketing Manager, LCM Genect
  • Peter French, Strategic Technology Advisor, Sienna Cancer Diagnostics

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Chapter Outlines:

Chapter 2 provides an executive summary of the insights captured in our research. It offers a high-level view on the current scenario within the liquid biopsy market and describes its evolution in the short-mid term and long term.

Chapter 3 provides an overview of cancer statistics and the global burden of the disease. In this section of the report, we have also highlighted the importance of early detection of the disease through diagnosis and asymptomatic screening. The chapter outlines the conventional invasive diagnostic tests, which are widely used for cancer diagnosis and prognosis.

Chapter 4 discusses, in detail, the need for non-invasive cancer diagnostics and their importance. The chapter presents the underlying concept of different imaging techniques, screening assays and advanced approaches used for diagnosis of cancer, highlighting the advantages and disadvantages of each of the aforementioned techniques.

Chapter 5 provides information on nearly 300 liquid biopsy tests that are either available or under development for multiple applications. It features a comprehensive list of product developers and analyses based on a number of parameters, such as year of establishment, company size, geographical location, current development status of various products (under development, research use only, and available), type of product (assay kits, software / algorithm, and device), type of tumor marker (ctDNA, cfDNA, CTCs, exosomes, and others), applications (early diagnosis, treatment selection, patient monitoring and recurrence monitoring), and target cancer indications.

Chapter 6 includes elaborate profiles of key players, featuring a brief overview of the company, its financial information (if available), a detailed description of its product portfolio, and an informed future outlook.

Chapter 7 features an in-depth analysis and discussion on the various collaborations and partnerships from 2016-2019 (till September), based on various parameters, such as, year of partnership, target cancer indications, type of type of tumor marker, and type of partnership model (namely mergers and acquisitions, licensing agreements, product development agreements, product development and commercialization agreements, research and development agreements, distribution and supply agreements, service agreements, clinical trial agreements and other agreements). It also includes a schematic representation that showcases the companies that have established the maximum number of alliances, highlighting most popular tumor markers and target disease indications.

Chapter 8 presents details on various investments received by the start-ups / small-sized and mid-sized companies that are engaged in this domain. It also includes an analysis of the funding instances that have taken place in the market, till September 2019, highlighting the growing interest of the venture capital community and other strategic investors within this market.

Chapter 9 features an analysis on the big pharma companies, highlighting the key focus areas of these players across various parameters, such as current stage of development, type of tumor marker, target cancer indications and key applications areas.

Chapter 10 includes a detailed acquisition target analysis, which takes into consideration the historical trend of activity of top acquirers, providing a means for industry stakeholders to identify potential acquisition targets across different geographies.

Chapter 11 provides an overview of the other non-invasive diagnostics for oncological disorders. It presents information on different diagnostics tests, including non-blood based biomarker detection tests (saliva-based biomarker detection, stool-based metabolic biomarker detection, skin-based biomarker detection, semen-based biomarker detection and urine based biomarker detection), DNA methylation detection test, fecal occult blood test and fecal immunochemical test, microRNA (miRNA) based test, pigmented lesion assay, stool DNA (sDNA) testing, and Volatile Organic Compound (VOC) detection test. The diagnostic procedures discussed in this chapter are backed up by several examples.

Chapter 12 presents an insightful market forecast analysis, highlighting the future potential of non-invasive cancer diagnostics, till the year 2030. We have segregated the opportunity of non-invasive cancer diagnostics on the basis of the type of tumor marker (ctDNA, cfDNA, CTCs, exosomes, and others), applications (early diagnosis, patient monitoring and recurrence monitoring), target disease indications (breast cancer, lung cancer, colorectal cancer, prostate cancer, bladder cancer, melanoma, gastric cancer, pancreatic cancer, ovarian cancer, and others), end users (hospitals, research institutes and others) and key geographical regions (the US, the UK, Germany, Italy, Spain, France, Japan, Australia, China, India, and Rest of the World).

Chapter 13 presents insights from the survey conducted on stakeholders involved in the development of different types of liquid biopsies and other non-invasive tests. The participants, who were primarily Director / CXO level representatives of their respective companies, helped us develop a deeper understanding on the nature of their products and the associated commercial potential.

Chapter 14 is a collection of interview transcripts of the discussions held with key stakeholders in this market. In this chapter, we have presented the details of interviews held with Shibichakravarthy Kannan (Founder and CEO, Theranosis Life Sciences), Abizar Lakdawalla (Founder, ProXeom), Philippe Nore (CEO and Co-founder, MiNDERA Corporation), Frank Szczepanski (President and CEO, IVDiagnostics), Mark Li (CEO, Resolution Bioscience), Joachim Fluhrer (Founder and Medical Director, Genostics), Brad Walsh (CEO, Minomic International), Anton Iliuk (President and Chief Technology Officer, Tymora Analytical Operations), Burkhard Jansen (Chief Medical Officer, DermTech), Christer Ericsson (Chief Scientific Officer, iCellate Medical), Jake Micallef (Chief Scientific Officer, VolitionRx), Nathalie Bernard (Marketing Director, OncoDNA), Riccardo Razzini (Sales and Marketing Manager, LCM Genect), and Peter French (Strategic Technology Advisor, Sienna Cancer Diagnostics).

Chapter 15 summarizes the entire report. It presents a list of key takeaways and offers our independent opinion on the current market scenario. Further, it captures the evolutionary trends that are likely to determine the future of this segment of the cancer diagnostics.

Chapter 16 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 17 is an appendix, which contains a list of companies and organizations mentioned in this report.

Table of Contents

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Cancer Statistics and Burden of the Disease
  • 3.3. Importance of Early Cancer Detection
  • 3.4. Cancer Screening and Diagnosis
  • 3.5. Conventional Invasive Cancer Diagnostic Tests
    • 3.5.1. Biopsy
  • . 3.5.1.1. Fine Needle Aspiration Biopsy
  • . 3.5.1.2. Core Needle Biopsy
  • . 3.5.1.3. Vacuum-Assisted Biopsy
  • . 3.5.1.4. Image-Guided Biopsy
  • . 3.5.1.5. Sentinel Node Biopsy
  • . 3.5.1.6. Surgical Biopsy
  • . 3.5.1.7. Endoscopic Biopsy
  • . 3.5.1.8. Bone Marrow Biopsy
    • 3.5.2. Endoscopy
  • 3.6. Need for Non-Invasive Approaches
  • 3.7. Liquid Biopsy: Diagnosing Circulating Biomarkers
    • 3.7.1. Circulating Tumor Cells
    • 3.7.2. Circulating Tumor DNA
    • 3.7.3. Exosomes
  • 3.8. Costs and Benefits Associated with Liquid Bi0psy and Non-Invasive Tests
  • 3.9. Emerging Trends in Intellectual Property Related to Non-Invasive Cancer Diagnostics
  • 3.10. Challenges Associated with Non-Invasive Cancer Diagnostics
  • 3.11. Future Perspectives

4. NON-INVASIVE CANCER SCREENING AND DIAGNOSIS

  • 4.1. Chapter Overview
  • 4.2. Diagnostic Imaging
    • 4.2.1. Magnetic Resonance Imaging (MRI)
    • 4.2.2. Mammography
    • 4.2.3. Bone Scan
    • 4.2.4. Computerized Tomography (CT) Scan
    • 4.2.5. Integrated Positron Emission Tomography (PET)-CT Scan
    • 4.2.6. Ultrasound
    • 4.2.7. X-ray Radiography (Barium Enema)
  • 4.3. Screening Assays
    • 4.3.1. Circulating Tumor Marker Test
    • 4.3.2. Digital Rectal Exam (DRE)
    • 4.3.3. Fecal Occult Blood Test (FOBT)
    • 4.3.4. Multigated Acquisition (MUGA) Scan
    • 4.3.5. Papanicolaou Test and Human Papilloma Virus Test
  • 4.4. Advanced Non-Invasive Approaches
    • 4.4.1. Cytogenetic / Gene Expression Studies
    • 4.4.2. Molecular Signature-based Non-Invasive Methods
    • 4.4.3. Saliva-based Oral Cancer Diagnostics
    • 4.4.4. Vital Staining
    • 4.4.5. Optical Biopsy
    • 4.4.6. Other Diagnostic Techniques

5. MARKET LANDSCAPE

  • 5.1. Chapter Overview
  • 5.2. Liquid Biopsy Products: List of Developers
    • 5.2.1. Analysis by Year of Establishment
    • 5.2.2. Analysis by Company Size and Geographical Location
    • 5.2.3. Leading Players
    • 5.2.4. Analysis by Geography
  • 5.3. Liquid Biopsy Products: List of Available / Under Development Products
    • 5.3.1. Analysis by Status of Development
    • 5.3.2. Analysis by Type of Product
    • 5.3.3. Analysis by Application Area
    • 5.3.4. Analysis by Target Cancer Indication
    • 5.3.5. Analysis by Type of Tumor Marker
    • 5.3.6. Analysis by End User
    • 5.3.7. Analysis by Turnaround Time
  • 5.4. Liquid Biopsy Products: List of Other Products, Kits and Consumables
  • 5.5. Liquid Biopsy Products: List of Contract Service Providers

6. COMPANY PROFILES

  • 6.1. Chapter Overview
  • 6.2. Amoy Diagnostics
    • 6.2.1. Company Overview
    • 6.2.2. Financial Information
    • 6.2.3. Liquid Biopsy Product Portfolio
    • 6.2.4. Recent Developments and Future Outlook
  • 6.3. DiaCarta
    • 6.3.1. Company Overview
    • 6.3.2. Liquid Biopsy Product Portfolio
    • 6.3.3. Recent Developments and Future Outlook
  • 6.4. HaploX
    • 6.4.1. Company Overview
    • 6.4.2. Liquid Biopsy Product Portfolio
    • 6.4.3. Recent Developments and Future Outlook
  • 6.5. NeoGenomics
    • 6.5.1. Company Overview
    • 6.5.2. Financial Information
    • 6.5.3. Liquid Biopsy Product Portfolio
    • 6.5.4. Recent Developments and Future Outlook
  • 6.6. QIAGEN
    • 6.6.1. Company Overview
    • 6.6.2. Financial Information
    • 6.6.3. Liquid Biopsy Product Portfolio
    • 6.6.4. Recent Developments and Future Outlook
  • 6.7. Swift Biosciences
    • 6.7.1. Company Overview
    • 6.7.2. Liquid Biopsy Product Portfolio
    • 6.7.3. Recent Developments and Future Outlook
  • 6.8. Sysmex Inostics
    • 6.8.1. Company Overview
    • 6.8.2. Liquid Biopsy Product Portfolio
    • 6.8.3. Recent Developments and Future Outlook
  • 6.9. Thermo Fisher Scientific
    • 6.9.1. Company Overview
    • 6.9.2. Financial Information
    • 6.9.3. Liquid Biopsy Product Portfolio
    • 6.9.4. Recent Developments and Future Outlook

7. PARTNERSHIPS AND COLLABORATIONS

  • 7.1. Chapter Overview
  • 7.2. Partnership Models
  • 7.3. List of Partnerships and Collaborations
    • 7.3.1. Analysis by Year of Partnership
    • 7.3.2. Analysis by Type of Partnership
    • 7.3.3. Analysis by Type of Tumor Marker
    • 7.3.4. Analysis by Target Cancer Indication
    • 7.3.5. Analysis by Type of Partner
    • 7.3.6. Most Active Players: Analysis by Number of Partnerships
    • 7.3.7. Regional Analysis
  • . 7.3.7.1. Intercontinental and Intracontinental Agreements

8. FUNDING AND INVESTMENT ANALYSIS

  • 8.1. Chapter Overview
  • 8.2. Types of Funding
  • 8.3. List of Funding and Investment Instances
    • 8.3.1. Analysis by Number of Funding Instances
    • 8.3.2. Analysis by Amount Invested
    • 8.3.3. Analysis by Type of Funding
    • 8.3.4. Analysis by Target Cancer Indication
    • 8.3.5. Analysis by Type of Tumor Marker
    • 8.3.6. Most Active Players: Analysis by Amount Invested
    • 8.3.7. Most Active Investors: Analysis by Number of Funding Instances
    • 8.3.8. Regional Analysis by Amount Invested
  • 8.4. Concluding Remarks

9. LIQUID BIOPSY: INITIATIVES OF BIG PHARMA PLAYERS

  • 9.1. Chapter Overview
  • 9.2. Top Pharmaceutical Companies
    • 9.2.1. Analysis by Status of Development
    • 9.2.2. Analysis by Type of Tumor Marker
    • 9.2.3. Analysis by Application Area
    • 9.2.4. Analysis by Target Cancer Indication

10. KEY ACQUISITION TARGETS

  • 10.1. Chapter Overview
  • 10.2. Scope and Methodology
  • 10.3. Scoring Criteria and Key Assumptions
  • 10.4. Potential Strategic Acquisition Targets in North America
  • 10.5. Potential Strategic Acquisition Targets in Europe
  • 10.6. Potential Strategic Acquisition Targets in Asia-Pacific / Rest of the World
  • 10.7. Concluding Remarks

11. OTHER NON-INVASIVE CANCER DIAGNOSTICS

  • 11.1. Chapter Overview
  • 11.2. Non-Blood-based Biomarker Detection Tests
  • 11.3. FOBT and Fecal Immunochemical Tests (FIT)
  • 11.4. Pigmented Lesion Assays
  • 11.5. Stool DNA (sDNA)-based Tests
  • 11.6. Volatile Organic Compound (VOC) Detection Tests
  • 11.7. Other Non-Invasive Cancer Diagnostics: Market Landscape

12. MARKET SIZING AND OPPORTUNITY ANALYSIS

  • 12.1. Chapter Overview
  • 12.2. Key Assumptions and Forecast Methodology
  • 12.3. Global Non-Invasive Cancer Diagnostics Market, 2019-2030
    • 12.3.1. Global Liquid Biopsy Market, 2019-2030
  • . 12.3.1.1. Global Liquid Biopsy Market: Distribution by Application Area, 2019-2030
  • . 12.3.1.1.1. Global Liquid Biopsy Market for Early Diagnosis, 2019-2030
  • . 12.3.1.1.2. Global Liquid Biopsy Market for Patient Monitoring, 2019-2030
  • . 12.3.1.1.3. Global Liquid Biopsy Market for Recurrence Monitoring, 2019-2030
  • . 12.3.1.2. Global Liquid Biopsy Market: Distribution by Target Cancer Indication, 2019-2030
  • . 12.3.1.2.1. Global Liquid Biopsy Market for Breast Cancer, 2019-2030
  • . 12.3.1.2.2. Global Liquid Biopsy Market for Lung Cancer, 2019-2030
  • . 12.3.1.2.3. Global Liquid Biopsy Market for Colorectal Cancer, 2019-2030
  • . 12.3.1.2.4. Global Liquid Biopsy Market for Prostate Cancer, 2019-2030
  • . 12.3.1.2.5. Global Liquid Biopsy Market for Bladder Cancer, 2019-2030
  • . 12.3.1.2.6. Global Liquid Biopsy Market for Melanoma, 2019-2030
  • . 12.3.1.2.7. Global Liquid Biopsy Market for Gastric Cancer, 2019-2030
  • . 12.3.1.2.8. Global Liquid Biopsy Market for Pancreatic Cancer, 2019-2030
  • . 12.3.1.2.9. Global Liquid Biopsy Market for Ovarian Cancer, 2019-2030
  • . 12.3.1.3. Global Liquid Biopsy Market: Distribution by Type of Tumor Marker, 2019-2030
  • . 12.3.1.3.1. Global Liquid Biopsy Market for ctDNA, 2019-2030
  • . 12.3.1.3.2. Global Liquid Biopsy Market for cfDNA, 2019-2030
  • . 12.3.1.3.3. Global Liquid Biopsy Market for CTCs, 2019-2030
  • . 12.3.1.3.4. Global Liquid Biopsy Market for Exosomes, 2019-2030
  • . 12.3.1.3.5. Global Liquid Biopsy Market for Other Tumor Markers, 2019-2030
  • . 12.3.1.4. Global Liquid Biopsy Market: Distribution by Type of Analyte, 2019-2030
  • . 12.3.1.4.1. Global Liquid Biopsy Market for Blood, 2019-2030
  • . 12.3.1.4.2. Global Liquid Biopsy Market for Other Body Fluids, 2019-2030 (USD Billion)
  • . 12.3.1.5. Global Liquid Biopsy Market: Distribution by End User, 2019-2030
  • . 12.3.1.5.1. Global Liquid Biopsy Market for Hospitals, 2019-2030
  • . 12.3.1.5.2. Global Liquid Biopsy Market for Research Institutes, 2019-2030
  • . 12.3.1.5.3. Global Liquid Biopsy Market for Other End Users, 2019-2030
  • . 12.3.1.6. Global Liquid Biopsy Market: Distribution by Geography, 2019-2030
  • . 12.3.1.6.1 Liquid Biopsy Market in the US, 2019-2030
  • . 12.3.1.6.2 Liquid Biopsy Market in the UK, 2019-2030
  • . 12.3.1.6.3 Liquid Biopsy Market in Germany, 2019-2030
  • . 12.3.1.6.4 Liquid Biopsy Market in France, 2019-2030
  • . 12.3.1.6.5 Liquid Biopsy Market in Italy, 2019-2030
  • . 12.3.1.6.6 Liquid Biopsy Market in Spain, 2019-2030
  • . 12.3.1.6.7 Liquid Biopsy Market in Japan, 2019-2030
  • . 12.3.1.6.8 Liquid Biopsy Market in China, 2019-2030
  • . 12.3.1.6.9 Liquid Biopsy Market in India, 2019-2030
  • . 12.3.1.6.10 Liquid Biopsy Market in Australia, 2019-2030
    • 12.3.2. Other Non-Invasive Cancer Diagnostics Market Forecast, 2019-2030

13. SURVEY INSIGHTS

  • 13.1. Chapter Overview
  • 13.2. Company Specifics of Respondents
  • 13.3. Designation of Respondents
  • 13.4. Type of Product Portfolio
  • 13.5. Types of Products / Services Offered
  • 13.6. Application Area
  • 13.7. Status of Development of the Products
  • 13.8. Likely Market Size

14. CONCLUSION

  • 14.1. Timely Disease Detection and Subsequent Monitoring are Critical Elements of Patient Care in the Field of Oncology
  • 14.2. Introduction of Sophisticated Molecular Diagnostics has Facilitated Better Cancer Management
  • 14.3. Liquid Biopsy has Emerged as a Reliable Alternative to the Invasive Methods of Diagnosis
  • 14.4. The Versatile and Patient Friendly Nature of these Diagnostic Tools Cater to a Wide Range of Applications
  • 14.5. The Interest is Gradually Rising with Participation of Several Start-ups Across Different Geographies
  • 14.6. In Addition to Liquid Biopsy, Development of Other Non-Invasive Tests will Further Strengthen the Ongoing Innovation
  • 14.7. Rising Venture Capital Support is Indicative of a Lucrative Future Potential
  • 14.8. Primarily Led by Liquid Biopsy, the Non-Invasive Cancer Diagnostics Market has Emerged as a Multi-Billion Dollar Market

15. EXECUTIVE INSIGHTS

  • 15.1. Chapter Overview
  • 15.2. Interview Transcript: Shibichakravarthy Kannan, Founder & Chief Executive Officer, Theranosis Life Sciences
  • 15.3. Interview Transcript: Anton Iliuk, President and Chief Technology Officer, Tymora Analytical Operations
  • 15.4. Interview Transcript: Peter French, Strategic Technology Advisor, Sienna Cancer Diagnostics
  • 15.5. Interview Transcript: Joachim Fluhrer, Founder and Medical Director, Genostics
  • 15.6. Interview Transcript: Brad Walsh, Chief Executive Officer, Minomic International
  • 15.7. Interview Transcript: Catalina Vasquez, Chief Operating Officer, Nanostics
  • 15.8. Interview Transcript: Burkhard Jansen, Chief Medical Officer, DermTech
  • 15.9. Interview Transcript: Frank Szczepanski, President and CEO, IVDiagnostics
  • 15.10. Interview Transcript: Riccardo Razzini, Sales and Marketing Manager, LCM Genect
  • 15.11. Interview Transcript: Nathalie Bernard, Marketing Director, OncoDNA
  • 15.12. Interview Transcript: Abizar Lakdawalla, Founder, Proxeom
  • 15.13. Interview Transcript: Mark Li, CEO, Resolution Bioscience
  • 15.14. Interview Transcript: Christer Ericsson, Chief Scientific Officer, iCellate Medical
  • 15.15. Interview Transcript: Philippe Nore, CEO and Co-founder, MiNDERA
  • 15.16. Interview Transcript: Jake Micallef, Chief Scientific Officer, VolitionRx

16. APPENDIX 1: TABULATED DATA

17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS